Q-omics provides the consensus-scored DBH profile across patient tissues and cancer cell-line models. DBH expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DBH is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, DBH protein abundance shows 24,499 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where DBH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DBH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DBH survival associations across molecular data types. DBH RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DBH RNA expression–survival associations across cancer types. High DBH expression shows unfavorable associations in KIRC, but favorable associations in HNSC, SKCM, BLCA, BRCA and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DBH RNA expression.
This table summarizes DBH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DBH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DBH shows lower tumor expression in THCA, KIRC, LIHC, KICH, KIRP and LUSC. The THCA box plot shows higher DBH RNA expression in normal versus tumor tissue (log2 FC = −1.114, t-test p < 0.001).
This table shows molecular features associated with DBH in patient tissues and cancer cell lines. In patient samples, DBH shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DBH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
